RELATED ARTICLES

• Presbyopia-Correcting IOLs for Glaucoma Patients

  Two clinicians discuss their approach to selecting IOLs for this patient population.

  by Steven D. Vold, MD, and Randall E. Cole, MD

• The Pathway to Medical Innovation

  For this roundtable discussion, not sponsored by industry, Glaucoma Today convened a panel to discuss needed innovation in glaucoma and the process of protecting new ideas and bringing them to market.

• A Replacement for Antimetabolites?

  Ologen is a new product that modulates wound healing in glaucoma surgery.

  by Steven R. Sarkisian, JR, MD

• Intellectual Property and Conflict of Interest

  If not protected, an idea will not benefit the creator, and industry will be less likely to have an interest in commercializing the concept.

  by Joel S. Schuman, MD, in an Interview with Glaucoma Today

• Are Your Patients Instilling Their Drops?

  Glaucoma Today asked several members of the glaucoma community the following question: How do you know whether patients are using their topical glaucoma medications?

  by Henry D. Jempel, MD, MHS; Kelly W. Muir, MD; Gary D. Novack, PHD; and Alan L. Robin, MD

▶